Aktiechat - investeringstips
Aktiesnakken
Genmab
Bavarian Nordic
TESLA
Chemometec
Zealand Pharma
Banker og Finans
Biotek-snakken
Gubra
Shipping
Grønne Aktier
Hansa Biopharma
NOVO
AMBU
BITCOIN
Amerikanske aktier
ExpreS2ion
Vestas
Medico
Pharma
EL-BILER
AI/Kunstig intelligens
Laks
GN Store Nord
OLIE OG GAS
Danske Bank
Ennogie
Smallcap og First North aktier
Krypto
11/5 16:37 af Helge Larsen/PI-redaktør |
This session is ended.
| |
11/5 16:36 af Jan Van de Winkel |
Thank you, for an energizing online chat. Look forward to next quarter.
| |
11/5 16:36 af Helge Larsen/PI-redaktør |
Jan and David. Thank You for joining us and thank you for the many fullfilling answers to our questions. We wish you a very good presentation at ASCO. We look forward to to seeing you back here on ProInvestor after Q2. :-)
| |
11/5 16:35 af Jan Van de Winkel |
(controlled growth)
| |
11/5 16:34 af Jan Van de Winkel |
We are anticipating controlled in all three of our sites and will expand departments carefully, depending on the needs of product development and markets served.
| |
11/5 16:34 af bongobob |
How many FTE’s do you plan for in the sales/commercial side?
| |
11/5 16:33 af Jan Van de Winkel |
Our technologies support the advancement of new exciting and differentiated products - we will continue to license access to our proprietary technologies.
| |
11/5 16:32 af bongobob |
Are you considering a spin off to capitalize on technologies?
| |
11/5 16:32 af Jan Van de Winkel |
Looking forward.
| |
11/5 16:32 af Helge Larsen/PI-redaktør |
Great. We have 2 questions more left for you.
| |
11/5 16:32 af Jan Van de Winkel |
The trial is progressing very well and we are swiftly moving through the dose escalation.
| |
11/5 16:31 af Sukkeralf |
Jan you mentioned in yesterdays CC that you already see activity with Humax-AXL ADC - is that at a lower dose than expected ?
| |
11/5 16:30 af Jan Van de Winkel |
We would expect interim data in 2018
| |
11/5 16:30 af Jedi |
What is the estimated time line for interim data from the Maia study?
| |
11/5 16:30 af Jan Van de Winkel |
Yes there is a prescheduled interim planned for Maia.
| |
11/5 16:29 af Jedi |
Have interim analyses been planned for the Maia DRd frontline study? If yes, how many events need to take place before the interim analysis?
| |
11/5 16:29 af Jan Van de Winkel |
this is a small set of patients, and so this is highly unlikely.
| |
11/5 16:28 af Bulder |
Is it your intention to ask for approval of dara+KRd frontline, since the data will be presented orally at ASCO?
| |
11/5 16:28 af Jan Van de Winkel |
We cannot comment on ongoing litigation
| |
11/5 16:27 af jkj |
What is the time frame for the lawsuit whit Morphosys
| |
11/5 16:27 af Jan Van de Winkel |
Usually you expect about a year from submission for approval. We submitted in late
December last year.
| |
11/5 16:27 af jkj |
what is the time frame for application submitted in Japan for daratumumab
| |
11/5 16:26 af Jan Van de Winkel |
This is the smoldering trial - maybe at a medical conference in the second half of the year.
| |
11/5 16:26 af Bulder |
When can we expect data from the Centaurus trial?
| |
| ||
11/5 16:26 af Jan Van de Winkel |
This is the majority of the frontline market which could grow due to new treatments becoming available to frontline patients.
| |
11/5 16:25 af Bulder |
Both Alcyone and Maia are for patients who are not candidates for auto-transplant. How big is this non-transplant part compared to the total frontline setting?
| |
11/5 16:24 af Jan Van de Winkel |
The study is progressing well and we will flag up once recruitment is complete.
| |
11/5 16:24 af Bulder |
Do you know how far Cassiopeia has come regarding recruitment?
| |
11/5 16:24 af Jan Van de Winkel |
The study is ongoing, it is up to the team involved to decide on timing for disclosure.
| |
11/5 16:23 af bibob |
When Can we expect news from the ATRA studies. ?
| |
11/5 16:23 af Jan Van de Winkel |
It is an ISS study which involves investigators in Amsterdam and Utrecht as well as colleagues in Janssen and will be reported by that team.
| |
11/5 16:22 af Bulder |
Will results from the dara-ATRA study be announced officially by Genmab?
| |
11/5 16:21 af Jan Van de Winkel |
We would anticipate data in 2018 as the study is presently active.
| |
11/5 16:21 af Vester |
When can we expect to learn more about the effects of Dara in combination with Tecentriq in NSCLC?
| |
11/5 16:21 af Jan Van de Winkel |
for renal cell carcinoma.
| |
11/5 16:20 af Jan Van de Winkel |
similarly strong data was published in Cell by Dr Chevrier et al....
| |
11/5 16:20 af Jan Van de Winkel |
The Chen data are very interesting and are strongly supportive of CD38 being a checkpoint molecule and highlights the potential significance of daratumumab as a immune oncology agent...
| |
11/5 16:19 af Vester |
A recent lung cancer study (by Limo Chen) shows that CD38 acts a mechanism of resistance in PD-L1 therapy. What are your thoughts about these findings?
| |
11/5 16:18 af Jan Van de Winkel |
The results are based on the number of events and currently it is projected for the end of Q3
| |
11/5 16:17 af Bulder |
You have previously said Alcyone data this summer. Now it is late autumn. Why is that?
| |
11/5 16:16 af Jan Van de Winkel |
three blood cancers are already evaluated in dara studies, NKTcell Lymphoma, MDS a
nd AML.
| |
11/5 16:15 af Jan Van de Winkel |
which led Janssen to not progress to Part 2 of the trial. However...Studies will be scheduled in hematological cancers by Janssen as well as doctors in multiple blood cancers....
| |
11/5 16:15 af Jan Van de Winkel |
The response rates observed were lower than the stringent futility thresholds set...
| |
11/5 16:14 af Sukkeralf |
I don´t quite understand the impact of the Carina study - so Jan could you please answer these two questions. Were the obtained response rates of a quality that Janssen still plans to start Darzalex combinations studies in MCL, FL or DLBCL ? Have Genmabs peaksale estimations for Darzalex in hematology changed after the Carina study was stopped ?
| |
11/5 16:13 af Jan Van de Winkel |
We are always scanning the landscape for complimentary technologies for Genmab as well as complimentary products that might fit into our pipeline but nothing concrete at this moment.
| |
11/5 16:12 af bibob |
Mr. Winkel. Are you looking for some small biotek compagnies technologies to take over in the near future. Or maybe make some tech deals with. ( partnerships ) ?
| |
11/5 16:12 af Jan Van de Winkel |
HexaBody DR5/DR5 and DuoBody CD3xCD20 towards the clinic.
| |
11/5 16:11 af Jan Van de Winkel |
We are making solid progress with our pipeline, advancing tisotumab vedotin and HuMax-AXL-ADC, as well as....
| |
11/5 16:10 af bibob |
Mr. Winkel. Are you coming closer to the next winner on your own , or closer to new partnerships. I Think that we are many who would like to hear about it.
| |
11/5 16:10 af Jan Van de Winkel |
We get mid single digit royalties
|